AURX — Nuo Therapeutics Share Price
0.000.00%
Last trade - 00:00- $74.44m
- $74.39m
- $1.37m
- 30
- 18
- 63
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 46.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -3922.68% | ||
| Operating Margin | -154.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.11 | 0.61 | 1.37 | n/a | n/a | 56.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Directors
- David Jorden CEO (53)
- Peter Clausen CSO (49)
- Shaun Martin OTH
- Lawrence Atinsky DRC
- Paul Mintz DRC
- Lyle Hohnke IND (72)
- Mark McLoughlin IND
- Eric Winzer IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 29th, 1998
- Public Since
- January 19th, 2017
- No. of Shareholders
- 800
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 46,819,888
- Address
- 8285 EL RIO, SUITE 150, HOUSTON, 77054
- Web
- https://www.nuot.com/
- Phone
- +1 8322369060
- Auditors
- Malone Bailey, LLP
Upcoming Events for AURX
Q2 2025 Nuo Therapeutics Inc Earnings Release
Similar to AURX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Nuo Therapeutics share price?
As of Today at 22:24 UTC, shares in Nuo Therapeutics are trading at $1.59. This share price information is delayed by 15 minutes.
How has the Nuo Therapeutics share price performed this year?
Shares in Nuo Therapeutics last closed at $1.59 and the price had moved by +98.75% over the past 365 days. In terms of relative price strength the Nuo Therapeutics share price has outperformed the S&P500 Index by +84.3% over the past year.
What are the analyst and broker recommendations for Nuo Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Nuo Therapeutics dividend yield?
Nuo Therapeutics does not currently pay a dividend.
Does Nuo Therapeutics pay a dividend?
Nuo Therapeutics does not currently pay a dividend.
When does Nuo Therapeutics next pay dividends?
Nuo Therapeutics does not currently pay a dividend.
How do I buy Nuo Therapeutics shares?
To buy shares in Nuo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nuo Therapeutics?
As of the previous close price of $1.59, shares in Nuo Therapeutics had a market capitalisation of $74.44m.
Where are Nuo Therapeutics shares listed?
Here are the trading details for Nuo Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AURX
What kind of share is Nuo Therapeutics?
Based on an overall assessment of its quality, value and momentum Nuo Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nuo Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Nuo Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuo Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +105.57%.
As of the last closing price of $1.59, shares in Nuo Therapeutics were trading +68.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nuo Therapeutics PE Ratio?
The Nuo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nuo Therapeutics?
Nuo Therapeutics' management team is headed by:
- David Jorden - CEO
- Peter Clausen - CSO
- Shaun Martin - OTH
- Lawrence Atinsky - DRC
- Paul Mintz - DRC
- Lyle Hohnke - IND
- Mark McLoughlin - IND
- Eric Winzer - IND